Adenocarcinoma of the Cervix Clinical Trial
Official title:
A Phase II Study of Pemetrexed in Recurrent Cervical Adenocarcinomas
Patients with advanced or recurrent adenocarcinoma or adenosquamous cell carcinoma of the cervix will receive Pemetrexed.
Patients will receive Pemetrexed 500 mg/m2 every three week.
On initiation of pemetrexed, on day one of first chemotherapy cycle, patients will begin
taking folic acid at a dose of 350 to 600 mcg daily as well as receive an intramuscular
injection of 1000 mcg of vitamin B12, with subsequent vitamin B12 injections given every 9
weeks while on study.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01639625 -
Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application
|
Phase 2 |